Related Experiment Video
Updated: Feb 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
A Multifactorial Case of Acquired Hemophilia A
Jason P Willis1, Timothy Kanne1, Alex Cole1
1Medicine, Edward Via College of Osteopathic Medicine, Auburn, USA.
None:
Acquired hemophilia A (AIHA) is a rare autoimmune bleeding disorder in which the body develops autoantibodies against factor VIII, leading to spontaneous bleeding. It has an incidence of about one person per million each year. AIHA carries high risks; these symptoms are only exacerbated with other comorbidities, as explored in this patient, a 73-year-old female patient with a history of heart disease, diabetes, hypertension, and a positive lupus anticoagulant (LA) test. She presented with a rapidly growing neck hematoma that compromised her airway, requiring immediate intubation and admittance to the ICU. Laboratory tests showed a severely prolonged activated partial thromboplastin time (aPTT) and critically low factor VIII levels, confirming the diagnosis of AIHA. Despite early treatment with corticosteroids, cyclophosphamide, rituximab, and recombinant factor VIIA, she experienced repeated bleeding episodes and developed complications such as neutropenic fever and refractory depression. Ultimately, due to the cumulative impact of these complications, she was transitioned to palliative care and died. This case highlights the importance of prompt diagnosis and treatment, the difficulties of balancing immunosuppression and bleeding risk, and the impact significant illnesses can have on mental health. Early recognition, multidisciplinary management, and individualized treatment strategies are crucial to improving outcomes in patients with this rare disorder.
More Related Videos
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Multiple Allele Traits
Blood Types
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...

